Lantheus Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LNTH in the last 30 days.
See all $LNTH insider activity →The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.
Lantheus (LNTH) stockholders will vote on a $102.50 cash-plus-CVR sale to Curium, delisting LNTH from Nasdaq. Each share gets $102.50 cash plus a CVR for up to $12.00 more if milestones are met by 2031. The board recommends approval, requiring a majority vote. The deal, valued at $7.45 billion, needs stockholder and regulatory approvals.
In August 2026, Curium agreed to acquire Lantheus Holdings (LNTH) for up to $8 billion, consolidating the radiopharmaceutical sector and creating a global nuclear medicine group. The deal spans diagnostics and therapeutics across 70+ countries.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning LNTH (Lantheus Holdings, Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent LNTH coverage spans regulation, mergers & acquisitions and earnings.
Adds a diagnostic product to Lantheus' imaging portfolio, potentially boosting sales.
If approved, LNTH will be acquired for cash and contingent payments, removing the stock from public markets.
The acquisition expands Curium's radiopharmaceutical portfolio and may boost LNTH's valuation.
Deal offer creates downside pressure; potential upside if premium improves.
FDA approval is a positive commercialization catalyst for LNTH’s Alzheimer’s imaging franchise, but the article flags execution and competitive risks.
AlphAI scores every news story that mentions LNTH with an AI model for sentiment and relevance, and aggregates insider trades from Lantheus Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.
3 min readLantheus (LNTH) stockholders will vote on a $102.50 cash-plus-CVR sale to Curium, delisting LNTH from Nasdaq. Each share gets $102.50 cash plus a CVR for up to $12.00 more if milestones are met by 2031. The board recommends approval, requiring a majority vote. The deal, valued at $7.45 billion, needs stockholder and regulatory approvals.
2 min readIn August 2026, Curium agreed to acquire Lantheus Holdings (LNTH) for up to $8 billion, consolidating the radiopharmaceutical sector and creating a global nuclear medicine group. The deal spans diagnostics and therapeutics across 70+ countries.
1 min readLantheus Holdings (LNTH) shares dropped 3% after-hours on reports of a $7B acquisition offer from Curium, valued at $102 per share upfront, below its $108.03 closing price. The deal includes $12.50 per share in contingent value rights, totaling $8B. No final agreement has been reached.
2 min readLantheus Holdings (Nasdaq: LNTH) said the FDA approved TAUKLARIFY, a tau PET imaging agent for Alzheimer’s disease diagnostics. The company said the agent is intended to visualize tau pathology to support more precise assessment. The article links the approval to Lantheus’ broader molecular imaging expansion beyond its existing products.
5 min readBiopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.
7 min readLantheus Holdings (NASDAQ: LNTH) said the FDA approved TAUKLARIFY (florquinitau F 18 injection), also known as MK-6240, for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease to identify tau NFT pathology. Approval is based on two blinded studies of 500+ subjects and safety in 1,734; common adverse reactions included headache and nausea.
6 min readLantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.
5 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Adjusted fully diluted earnings per share of
6 min readLantheus Holdings (NASDAQ: LNTH) is set to report Q2 results Thursday before the bell. The article notes it beat prior-quarter revenue expectations with $377.3 million revenue, up 1.2% YoY, but missed full-year revenue guidance expectations. For the upcoming quarter, analysts expect revenue down 4.7% YoY. LNTH shares are down 1.8% over a month; average analyst price target is $107.22 vs $100.97.
3 min read
